St. Luke's Hospital S.A.
- Address
- lock Available on a paid plan
Neoplasms and Oncology
At St. Luke's Hospital S.A. in Thessaloniki, the Department of Medical Pathology & Oncology is conducting clinical research focused on a wide range of cancers, especially lung cancer, breast cancer, and head and neck cancer. These studies are designed to evaluate new treatment options, compare them with current standards of care, and improve outcomes for people with advanced or early-stage disease.
- Research in small cell lung cancer is assessing whether a new therapy can improve survival compared with standard treatment.
- Studies in non-small cell lung cancer are examining targeted approaches for tumors with KRAS G12C mutations and related advanced disease settings.
- Trials in ER+/HER2- early breast cancer are evaluating strategies to reduce the risk of recurrence after standard endocrine therapy.
- Work in head and neck cancer is testing novel immunotherapy combinations to strengthen antitumor activity in recurrent or metastatic disease.
The site’s oncology program also includes studies in solid tumors more broadly, reflecting an effort to expand precision medicine and better match treatments to tumor biology.
Nervous System Diseases and Neurology
Clinical trials at this hospital also address nervous system diseases, with a particular focus on multiple sclerosis. This research is centered on understanding the long-term safety and tolerability of new treatment approaches, with the goal of supporting people living with relapsing and progressive forms of the disease.
- Studies in multiple sclerosis are evaluating whether emerging therapies can be used safely over time in both relapsing and progressive disease.
- The research aims to improve treatment options for patients whose symptoms and disease course require ongoing management.
- These trials contribute to better knowledge of how to balance effectiveness with long-term tolerability in chronic neurological care.
This area of research adds an important neurology dimension to the site’s clinical trial portfolio, complementing its broader focus on complex disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 134 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 134 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
- 1AstraZeneca AB4active
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St. Luke's Hospital S.A.
lock Showing 1 of 76 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 134 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 15 | Unknown | 2021-03-17 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.